A Phase 3 interventional study of Plecanatide in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 220 sites in 2 countries. Open to participants aged 18 Years to 81 Years. Per ClinicalTrials.gov, last updated 2019-07-02.
Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 71 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.
Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 4th largest by enrollment of the 260 interventional ones that give a count, is one of 14 that started in 2013, is one of 30 in phase 3, and was the 116th registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Sarah Nikiforow, MD · Sites in United States
Ages 2+
Incyte Corporation · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–17
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 81 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
300 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 117 · Phase 3 33 · Phase 4 18
First in 2001; this study’s year is marked. 14 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,370 is above the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 45 across the 260 interventional studies, 187 across the 39 observational. Of the 209 that completed or were terminated, 110 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
112 of 300 have an industry lead sponsor. The 10 most frequent:
This study is registered under Bausch Health Americas, Inc., one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.
Bausch Health Companies Inc. has 2 studies filed under Bronchiolitis Obliterans Syndrome — fewer than ten, so there is no comparison to draw.
20 of the studies in Bronchiolitis Obliterans Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT07395232Phase 3Dompé Farmaceutici S.p.AAn Efficacy and Safety Study of DFL24498 in the Treatment of AKC | 2027-03 |
| NCT02181257Phase 3Washington University School of MedicineExtracorporeal Photopheresis for Medicare Recipients of Lung Allografts | 2027-04 |
| NCT06585774Phase 3Incyte CorporationA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2027-09-28 |
| NCT06018766Steven Hays, MDLAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
This is an open-label extension study of plecanatide in the treatment of patients with CIC who previously completed Synergy Protocols SP304-20210 and SP304203-00 (The CIC3 Study).
The planned duration of each patient's study participation is up to 411 days, including up to 33 days of screening, 8 study visits over 52 weeks of treatment and a follow-up visit 2 weeks after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks
Drug: Plecanatide
Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks
Drug: Plecanatide
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)
All clinically significant findings upon Physical Examinations of the Safety Population during the treatment period were reported as TEAEs. Safety was evaluated based on number of patients who experienced at least one TEAE.
Time frame: From first dose up to 72 weeks
Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide
Tolerability was evaluated based on number of patients who experienced at least one TEAE leading to discontinuation of the study drug
Time frame: From first dose up to 72 weeks
Summary of Vital Signs at >Day 364 - Blood Pressure (Systolic and Diastolic; mmHg)
The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).
Time frame: From first dose up to 72 weeks
Summary of Vital Signs at >Day 364 - Heart Rate (Beats Per Minute)
The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).
Time frame: From first dose up to 72 weeks
Summary of Vital Signs at >Day 364 - Body Temperature (°C)
The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).
Time frame: From first dose up to 72 weeks
Summary of Vital Signs at >Day 364 - Respiration Rate (Breaths Per Minute)
The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).
Time frame: From first dose up to 72 weeks
Summary of ECG Results Shift From Baseline at > Day 364
Baseline was defined as the last non-missing value collected prior to first dose of study drug)
Time frame: From first dose up to 72 weeks
Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline
Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study. The Common Terminology Criteria for Adverse Events (CTCAE), Grades 1 through 5 were used for descriptions of severity for each Adverse Event (AE): Grade 1 - Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2 - Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental Activities of Daily Living (ADL); Grade 3 - Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; Grade 4 - Life-threatening consequences; urgent intervention indicated; Grade 5 - Death related to AE.
Time frame: From first dose up to 72 weeks
Summary of Patient Patient Global Assessment (PGA) for Constipation Severity at > Day 364
Constipation severity was measured using a 5-point score: 1=None, 2=Mild, 3=Moderate, 4=Severe, 5=Very severe Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study.
Time frame: Form first dose up to 72 weeks
Summary of Patient Global Assessment (PGA) for Constipation - Change From Baseline to > Day 364
Change of Constipation measured using a 7-point score: 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No change, 5=Minimally Worse, 6=Much Worse, 7=Very Much Worse Baseline is defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study.
Time frame: From first dose up to 72 weeks
Summary of Patient Global Assessment (PGA) for Treatment Satisfaction at > Day 364
Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study. Treatment Satisfaction was measured using a 5-point score: 1=Not At All Satisfied, 2=A Little Satisfied, 3=Moderately Satisfied, 4=Quite Satisfied, 5=Very Satisfied.
Time frame: From first dose up to 72 weeks
Summary of Patient Global Assessment (PGA) for Treatment Continuation at End of Treatment
Treatment continuation was measured using 5-point score: 1=Not At All Likely, 2=A Little Likely, 3=Moderately Likely, 4=Quite Likely, 5=Very Likely
Time frame: From first dose up to 72 weeks
Patients with CIC who completed the double-blind phase 2b (NCT01429987) study, or phase 3 (NCT01982240 or NCT0222471) studies or who screen-failed for the phase 3 studies due solely to pre-treatment diary compliance and met all of the inclusion criteria and none of the exclusion criteria enrolled into this open-label study.
| Milestone | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Started | 224 | 2146 |
| Completed | 171 | 1761 |
| Not completed | 53 | 385 |
All clinically significant findings upon Physical Examinations of the Safety Population during the treatment period were reported as TEAEs. Safety was evaluated based on number of patients who experienced at least one TEAE.
| Participants | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) | 123 | 620 |
Tolerability was evaluated based on number of patients who experienced at least one TEAE leading to discontinuation of the study drug
| Participants | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of Plecanatide | 14 | 111 |
The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).
| mmHg | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Systolic Blood Pressure | 121 ± 13.40 | 122.9 ± 14.11 |
| Diastolic Blood Pressure | 75.7 ± 9.19 | 76.5 ± 8.47 |
The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).
| beats per minute | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Summary of Vital Signs at >Day 364 - Heart Rate (Beats Per Minute) | 71.2 ± 10.03 | 71.9 ± 9.30 |
The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).
| °C | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Summary of Vital Signs at >Day 364 - Body Temperature (°C) | 36.62 ± 0.329 | 36.59 ± 0.378 |
The vital signs included in the assessments were blood pressure (systolic and diastolic; mmHg), heart rate (beats per minute), body temperature (°C) and respiration rate (breaths per minute).
| breaths per minute | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Summary of Vital Signs at >Day 364 - Respiration Rate (Breaths Per Minute) | 15.7 ± 2.03 | 16.0 ± 2.31 |
Baseline was defined as the last non-missing value collected prior to first dose of study drug)
| participants | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Change from Normal to Abnormal | 27 | 42 |
| Change from Adnormal to Normal | 15 | 44 |
Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study. The Common Terminology Criteria for Adverse Events (CTCAE), Grades 1 through 5 were used for descriptions of severity for each Adverse Event (AE): Grade 1 - Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2 - Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental Activities of Daily Living (ADL); Grade 3 - Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL; Grade 4 - Life-threatening consequences; urgent intervention indicated; Grade 5 - Death related to AE.
| participants | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From Baseline | 192 | 1498 |
Constipation severity was measured using a 5-point score: 1=None, 2=Mild, 3=Moderate, 4=Severe, 5=Very severe Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study.
| score on a scale | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Summary of Patient Patient Global Assessment (PGA) for Constipation Severity at > Day 364 | 1.8 ± 0.94 | 1.7 ± 0.89 |
Change of Constipation measured using a 7-point score: 1=Very Much Improved, 2=Much Improved, 3=Minimally Improved, 4=No change, 5=Minimally Worse, 6=Much Worse, 7=Very Much Worse Baseline is defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study.
| score on a scale | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Summary of Patient Global Assessment (PGA) for Constipation - Change From Baseline to > Day 364 | 1.8 ± 0.94 | 1.7 ± 0.89 |
Baseline was defined as the last non-missing value collected prior to first dose of study drug within a given entry into the study. Treatment Satisfaction was measured using a 5-point score: 1=Not At All Satisfied, 2=A Little Satisfied, 3=Moderately Satisfied, 4=Quite Satisfied, 5=Very Satisfied.
| score on a scale | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Summary of Patient Global Assessment (PGA) for Treatment Satisfaction at > Day 364 | 4.1 ± 1.13 | 4.2 ± 1.02 |
Treatment continuation was measured using 5-point score: 1=Not At All Likely, 2=A Little Likely, 3=Moderately Likely, 4=Quite Likely, 5=Very Likely
| score on a scale | Plecanatide 3 mg | Plecantide 6 mg |
|---|---|---|
| Summary of Patient Global Assessment (PGA) for Treatment Continuation at End of Treatment | 4.1 ± 1.22 | 4.1 ± 1.16 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Plecanatide 3 mg | 0/224 (0%) | 8/224 (3.6%) | 32/224 (14.3%) |
| Plecanatide 6 mg | 1/2,146 (0%) | 32/2,146 (1.5%) | 188/2,146 (8.8%) |
| Event | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|
| DiverticulitisInfections and infestations | 2/224 | 0/2146 |
| PregnancyPregnancy, puerperium and perinatal conditions | 1/224 | 7/2146 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/224 | 1/2146 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/224 | 1/2146 |
| Atrial fibrillationCardiac disorders | 1/224 | 1/2146 |
| Calculus uretericRenal and urinary disorders | 1/224 | 0/2146 |
| HydronephrosisRenal and urinary disorders | 1/224 | 0/2146 |
| Bile duct stoneHepatobiliary disorders | 1/224 | 0/2146 |
| HypotensionVascular disorders | 1/224 | 0/2146 |
| Psychotic disorderPsychiatric disorders | 1/224 | 0/2146 |
| Event | Plecanatide 3 mg | Plecanatide 6 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 19/224 | 150/2146 |
| Urinary tract infectionInfections and infestations | 13/224 | 38/2146 |
A total of 2321 patients were based on the Safety Population (2370) excluding all duplicate patients except identified as "Index" patients. "Index" was duplicate patients appeared the first time in the enrollment.
| Age, Continuous(years) | Plecanatide 3 mg | Plecanatide 6 mg | Total |
|---|---|---|---|
| Mean | 48.9 ± 11.78 | 46.8 ± 14.03 | 47.0 ± 13.84 |
| Sex: Female, Male(Participants) | Plecanatide 3 mg | Plecanatide 6 mg | Total |
|---|---|---|---|
| Female | 190 | 1687 | 1877 |
| Male | 34 | 410 | 444 |
Showing the first 100 of 220 sites across 2 countries. Choose a country and city above to see the rest.
The record gives a start of Aug 2013, a primary completion of Jan 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2019, 3 years 6 months after primary completion. A results delay was requested in Aug 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plecanatide
Bronchiolitis Obliterans Syndrome →
Bausch Health Americas, Inc. →